Abstracts Archive - Page 2365 of 2607 - ACR Meeting Abstracts

Abstract Number: 995 • 2013 ACR/ARHP Annual Meeting
Quality Of Life, Productivity Impairment, Disease Severity and Health Care Costs In Relation To Functional Impairment In Psoriatic Arthritis Patients In The Czech Republic
Jiri Stolfa^1,2, Liliana Sedova^1,2, David Suchy³, Jiri Klimes⁴, Milan Vocelka⁴ and Tomas Dolezal⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Clinic of Rheumatology, Charles University Prague, Prague, Czech Republic, ³Department of Clinical Pharmacology, Rheumatology, University hospital Plzen, Plzen, Czech Republic, ⁴Institute of Health Economics and Technology Assessment, Charles University, Prague, Czech Republic
Background/Purpose: Our aim was to describe the QoL, productivity impairment, clinical indicators and health care costs in relationship to functional status described by Health assessment…
Abstract Number: 996 • 2013 ACR/ARHP Annual Meeting
Predictors and Modeling of Costs in Rheumatoid Arthritis
Jonas Eriksson¹, Thomas Frisell², Johan Askling³ and Martin Neovius¹, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Costs in RA are substantial with 2-3 times higher mean annual costs than in the general population, but with a skewed cost distribution.[1] As…
Abstract Number: 997 • 2013 ACR/ARHP Annual Meeting
Does Biologic Treatment For Rheumatoid Arthritis Offset Health Care Costs In Patients With Rheumatoid Arthritis? An Instrumental Variable Approach Using Administrative Data
Nick Bansback¹, Eric Fu², Daphne Guh², Huiying Sun², Wei Zhang², Diane Lacaille^3,4 and Aslam H. Anis¹, ¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ²St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ⁴Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Expenditure on biologic therapies for rheumatoid arthritis (RA) accounts for the highest pharmaceutical spending in many western healthcare systems. Given their clinical benefit with…
Abstract Number: 998 • 2013 ACR/ARHP Annual Meeting
Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis
Jinoos Yazdany¹, R. Adams Dudley², Randi Chen³ and Chien-Wen Tseng⁴, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California San Francisco Philip R. Lee Institute for Health Policy Studies, San Francisco, CA, ³Pacific Health Research and Education Institute, Honolulu, HI, ⁴Dept of Family Medicine and Community Health, University of Hawaii and Pacific Health Research and Education Institute, Honolulu, HI
Background/Purpose : Biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs) significantly reduce pain, disability and mortality in rheumatoid arthritis (RA). We evaluated how well RA drugs…
Abstract Number: 999 • 2013 ACR/ARHP Annual Meeting
Cost Consideration For Biologics For Patients With Rheumatoid Arthritis In a Pharmacy Benefit Management Setting
Ning Wu¹, Yuan-Chi Lee², Neel Shah³ and David J. Harrison³, ¹Economic Analysis and Solutions, United BioSource Corporation, Lexington, MA, ²United BioSource Corporation, Lexington, MA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Of the seven biologics FDA-approved for the treatment of moderate to severe rheumatoid arthritis (RA) as of August 2011, etanercept, adalimumab, certolizumab, and golimumab…
Abstract Number: 1000 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Cost-Effectiveness Of The Treatment Strategies With and Without Biological Response Modifiers For Patients With Recently Diagnosed Rheumatoid Arthritis Following A Clinical Guideline For Treatment Selection
An Tran-Duy¹, Annelies Boonen², Wietske Kievit³, Piet L.C.M. van Riel⁴, Mart A.F.J. van de Laar⁵ and Johan L. Severens⁶, ¹Department of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, ⁶Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands
Background/Purpose: In clinical practice, management of rheumatoid arthritis (RA) is characterized by a sequence of drugs which is determined based on patient characteristics, notably disease…
Abstract Number: 1001 • 2013 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Cost Per Effectively Treated Patient With Biologics Used In Rheumatoid Arthritis
Vernon F. Schabert¹, Jason Yeaw², Jonathan Korn¹, Caroleen Quach³, David J. Harrison⁴, Huifeng Yun⁵, George Joseph⁶, David H. Collier⁴ and Jeffrey R. Curtis⁷, ¹IMS Health, Alexandria, VA, ²IMS Consulting Group, Alexandria, VA, ³Public Health Policy and Management, University of North Carolina at Chapel Hill, Gillings School of Public Health, Chapel Hill, NC, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Former Amgen Employee, Thousand Oaks, CA, ⁷Epidemiology, University of Alabama at Birmingham, School of Public Health, Birmingham, AL
Background/Purpose: Previous work compared one-year cost per effectively treated patient with biologics for rheumatoid arthritis (RA) using a published, claims-based algorithm.1 Longer term comparisons are…
Abstract Number: 1003 • 2013 ACR/ARHP Annual Meeting
Measuring Economic Value of Morning Stiffness; Consistency Over 1 Year
Risto Tuominen, Public Health, University of Turku, Turku, Finland
Background/Purpose: Economic evaluation of health care activities requires often measuring clinical symptoms and their changes also in monetary terms. Patients with rheumatoid arthritis (RA) may…
Abstract Number: 1004 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis Of Two Rituximab Based Therapeutic Regimens For Longstanding Rheumatoid Arthritis
Luca Quartuccio¹, Rossella Di Bidino², Matteo Ruggeri³, Domenico Biasi⁴, Franco Schiavon⁵, Leonardo Punzi⁶, Silvano Adami⁷, Americo Cicchetti³ and Salvatore De Vita⁸, ¹Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ²HTA Unit, “A.Gemelli” Teaching Hospital, Rome, Italy, ³Faculty of Economics, Catholic University of the Sacred Heart, Rome, Italy, ⁴Rheumatology Clinic, University of Verona, Verona, Italy, ⁵Rheumatology Clinic, University of Padova, Padova, Italy, ⁶University of Padova, Rheumatology Unit, Padova, Italy, ⁷Rheumatology Department, University of Verona, Verona, Italy, ⁸Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: socioeconomic costs of rheumatoid arthritis (RA) are very high. Biologic therapies with different biologic targets are now available for moderate to severe RA, and…
Abstract Number: 1005 • 2013 ACR/ARHP Annual Meeting
Generalization and Extrapolation Of Treatment Effects From Clinical Studies In Rheumatoid Arthritis
Sandhya C. Nair¹, Wietske Kievit², R W Janse³, Johannes WJ Bijlsma⁴, Floris Lafeber⁵, Jaap Fransen⁶ and P.M.J. Welsing⁷, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Medical student, Utrecht, Netherlands, ⁴Dept of Rheumatology and Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Randomized clinical trials (RCTs) are accepted as the ‘gold standard’ to evaluate the efficacy/effectiveness of treatment. However, generalizing results from RCTs to daily practice…
Abstract Number: 1006 • 2013 ACR/ARHP Annual Meeting
One-Year Change Of Employment and Work Productivity In Patients With Systemic Lupus Erythematosus From The Southeastern United States
Deepak Sree¹, S. Sam Lim², Hong Kan³, Priti M. Jhingran³, Charles T. Molta⁴, Gaobin Bao⁵ and Cristina Drenkard^1,6, ¹Department of Medicine, Emory University, Atlanta, GA, ²Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ³GlaxoSmithKline, Research Triangle Park, NC, ⁴GlaxoSmithKline, King of Prussia, PA, ⁵Medicine, Emory University, Atlanta, GA, ⁶Epidemiology, Emory Rollins School of Public Health, Atlanta, GA
Background/Purpose: Different factors influence employment and work productivity in systemic lupus erythematosus (SLE) patients, including disease activity, cognitive impairment, comorbidities, education, and psychosocial factors. Previous…
Abstract Number: 1007 • 2013 ACR/ARHP Annual Meeting
Dose Of Corticosteroid, Risk Of Adverse Events and Healthcare Resource Utilization In Systemic Lupus Erythematosus
Wei-Shi Yeh¹, Shih-Yin Chen², Kathleen McCarty³, Qian Li², Yuan-Chi Lee² and Nathalie Franchimont³, ¹Biogen Idec, Cambridge, MA, ²United BioSource Corporation, Lexington, MA, ³Biogen Idec Inc., Weston, MA
Background/Purpose: Gluco-corticosteroids (GCs) are frequently used to treat autoimmune disease and their chronic use has long been known to cause adverse events (AEs). The purpose…
Abstract Number: 1008 • 2013 ACR/ARHP Annual Meeting
Longitudinal Analysis Of Direct Medical Costs For Systemic Sclerosis Patients: A Population-Based Study
Natalie McCormick¹, Carlo A. Marra², Eric C. Sayre³ and J. Antonio Avina-Zubieta⁴, ¹Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada
Background/Purpose: Patients with systemic sclerosis (SSc) have considerable morbidity which may be associated with high health resource utilization. Studies on health use and costs are…
Abstract Number: 1009 • 2013 ACR/ARHP Annual Meeting
Association Of Depressive Symptomatology and Life and Job Satisfaction In Patients With Rheumatoid Arthritis
Jutta G. Richter¹, Dr. Ralph Brinks², Thomas Muth³, Mia Vidakovic⁴, Tobias Koch¹, Peter Angerer³ and Matthias Schneider¹, ¹Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ³Institute for Occupational and Social Medicine, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁴Department of Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: Life satisfaction (LS) has become an important outcome measure in healthcare, is a relevant indicator of job satisfaction, and might be influenced by depression.…
Abstract Number: 1010 • 2013 ACR/ARHP Annual Meeting
Association Of Depressive Symptomatology and Life and Job Satisfaction In Patients With Systemic Lupus Erythematosus
Jutta G. Richter¹, Thomas Muth², Ralph Brinks³, Mia Vidakovic⁴, Tobias Koch¹, Peter Angerer² and Matthias Schneider¹, ¹Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Institute for Occupational and Social Medicine, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ³Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ⁴Department of Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: Life satisfaction (LS) has become an increasingly important outcome measure in healthcare, is a relevant indicator of job satisfaction and might be associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].